TY - JOUR
T1 - Influence of hospital volume on bleeding after endoscopic submucosal dissection for early gastric cancer in Japan
T2 - a multicenter propensity score-matched analysis
AU - Yabuuchi, Yohei
AU - Hatta, Waku
AU - Tsuji, Yosuke
AU - Yoshio, Toshiyuki
AU - Kakushima, Naomi
AU - Hoteya, Shu
AU - Doyama, Hisashi
AU - Nagami, Yasuaki
AU - Hikichi, Takuto
AU - Kobayashi, Masakuni
AU - Morita, Yoshinori
AU - Sumiyoshi, Tetsuya
AU - Iguchi, Mikitaka
AU - Tomida, Hideomi
AU - Inoue, Takuya
AU - Mikami, Tatsuya
AU - Hasatani, Kenkei
AU - Nishikawa, Jun
AU - Matsumura, Tomoaki
AU - Nebiki, Hiroko
AU - Nakamatsu, Dai
AU - Ohnita, Ken
AU - Suzuki, Haruhisa
AU - Ueyama, Hiroya
AU - Hayashi, Yoshito
AU - Sugimoto, Mitsushige
AU - Yamaguchi, Shinjiro
AU - Michida, Tomoki
AU - Yada, Tomoyuki
AU - Asahina, Yoshiro
AU - Narasaka, Toshiaki
AU - Kuribayashi, Shiko
AU - Kiyotoki, Shu
AU - Mabe, Katsuhiro
AU - Fujishiro, Mitsuhiro
AU - Masamune, Atsushi
AU - Ono, Hiroyuki
N1 - Funding Information:
We thank all collaborators in the Fight-Japan study group for the enrollment of patients and data collection: Sho Shiroma (Cancer Institute Hospital, Japanese Foundation for Cancer Research); Hiroyuki Odagiri (Toranomon Hospital); Kazuhiro Matsunaga and Shigenori Wakita (Ishikawa Prefectural Central Hospital); Masaki Ominami and Taishi Sakai (Osaka City University Graduate School of Medicine); Yuko Miura (The University of Tokyo); Minami Hashimoto, Jun Nakamura, and Ko Watanabe (Fukushima Medical University Hospital); Ryusuke Ariyoshi (Kobe University Graduate School of Medicine); Yutaka Okagawa, Takeyoshi Minagawa, and Ryoji Fujii (Tonan Hospital); Takao Maekita and Kazuhiro Fukatsu (Wakayama Medical University); Yoichi Hiasa (Ehime University Graduate School of Medicine); Daisuke Chinda, Hidezumi Kikuchi, and Tetsuya Tatsuta (Hirosaki University Hospital); Atsushi Goto (Yamaguchi University Graduate School of Medicine); Daisuke Maruoka, Kenichiro Okimoto, and Naoki Akizue (Chiba University Graduate School of Medicine); Tomoaki Yamasaki, Takehisa Suekane, and Yu Yasui (Osaka City General Hospital); Tsutomu Nishida and Masashi Yamamoto (Toyonaka Municipal Hospital); Keiichi Hashiguchi and Naoyuki Yamaguchi (Nagasaki University Hospital); Yoichi Akazawa and Hiroyuki Komori (Juntendo University School of Medicine); Yoshiki Tsujii, Hideki Iijima, and Tetsuo Takehara (Osaka University Graduate School of Medicine); Takashi Ohta (Kansai Rosai Hospital); Hidehiko Takabayashi (Saitama Medical Centre), Yoshiyuki Itakura (Kohnodai Hospital, National Centre for Global Health and Medicine); Kazuya Kitamura (Kanazawa University Hospital); Daisuke Akutsu (University of Tsukuba); and Toshio Uraoka (Gunma University Graduate School of Medicine). Moreover, we would like to thank Hajime Yamakage (Satista Co., Ltd.) who assisted with the statistical analyses.
Funding Information:
Yosuke Tsuji declared that he received personal fees from Olympus, Daiichi Sankyo, AstraZeneca, and Takeda Pharmaceutical and research grants from HOYA Pentax, Gunze, and Nipro outside the submitted work. Toshiyuki Yoshio declared that he received research grants from Takeda Science Foundation and JSPS KAKENHI Grant (number 19K08408) outside the submitted work. Hisashi Doyama declared that he received personal fees from Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, Eisai, EA Pharma, AstraZeneca, and Olympus outside the submitted work. Mitsuhiro Fujishiro declared that he received personal fees from Takeda Pharmaceutical, EA Pharma, and Nihon Pharmaceutical and that his department received research grants from HOYA Pentax, EA Pharma, Eisai, Taiho Pharmaceutical, AbbVie GK, Nippon Kayaku, Chugai Pharmaceutical, Gilead Sciences, Kyorin Pharmaceutical, and Mitsubishi Tanabe Pharma outside the submitted work. Atsushi Masamune declared that he received personal fees from EA Pharma, Takeda Pharmaceutical, Daiichi Sankyo Co., and Lylan.co.jp, and commercial research funding from Otsuka Pharmaceutical, EA Pharma, Gilead Sciences, Asahi Kasei Pharma, Eisai, AbbVie GK, Takeda Pharmaceutical, and Daiichi Sankyo outside the submitted work. Hiroyuki Ono declared that he received personal fees from Otsuka Pharmaceutical, EA Pharma, Boston Scientific, AstraZeneca, and Olympus outside the submitted work. Yohei Yabuuchi, Waku Hatta, Naomi Kakushima, Shu Hoteya, Yasuaki Nagami, Takuto Hikichi, Masakuni Kobayashi, Yoshinori Morita, Tetsuya Sumiyoshi, Mikitaka Iguchi, Hideomi Tomida, Takuya Inoue, Tatsuya Mikami, Kenkei Hasatani, Jun Nishikawa, Tomoaki Matsumura, Hiroko Nebiki, Dai Nakamatsu, Ken Ohnita, Haruhisa Suzuki, Hiroya Ueyama, Yoshito Hayashi, Mitsushige Sugimoto, Shinjiro Yamaguchi, Tomoki Michida, Tomoyuki Yada, Yoshiro Asahina, Toshiaki Narasaka, Shiko Kuribayashi, Shu Kiyotoki, and Katsuhiro Mabe have no conflicts of interest or financial ties to disclose.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/6
Y1 - 2022/6
N2 - Background: Information on whether there is a relationship between hospital volume and bleeding after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) is limited. This study aimed to compare the bleeding rates after ESD for EGC according to the hospital volume. Methods: Patients who underwent ESD for EGC at 33 institutions in Japan between November 2013 and October 2016 were included in this multicenter retrospective study. Hospital volume was categorized into three groups, based on the average annual number of ESD procedures: low- and medium-volume group (LMVG), high-volume group (HVG), and very high-volume group (VHVG). The bleeding rate after ESD for EGC was compared between the three hospital volume groups after propensity score matching. Results: A total of 10,320 patients, including 2797 patients in the LMVG, 4646 patients in the HVG, and 2877 patients in the VHVG, were identified. Propensity score matching yielded 2002 patients in each hospital volume group, with an improved balance of confounding variables between the three groups. The bleeding rates in the LMVG, HVG, and VHVG were 4.3%, 3.7%, and 4.9%, respectively, and no significant difference was noted between the three groups. Conclusions: The bleeding rate after ESD for EGC did not differ between hospitals in Japan. The finding indicated that ESD for EGC is equally feasible across Japanese hospitals of different volumes regarding bleeding after ESD.
AB - Background: Information on whether there is a relationship between hospital volume and bleeding after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) is limited. This study aimed to compare the bleeding rates after ESD for EGC according to the hospital volume. Methods: Patients who underwent ESD for EGC at 33 institutions in Japan between November 2013 and October 2016 were included in this multicenter retrospective study. Hospital volume was categorized into three groups, based on the average annual number of ESD procedures: low- and medium-volume group (LMVG), high-volume group (HVG), and very high-volume group (VHVG). The bleeding rate after ESD for EGC was compared between the three hospital volume groups after propensity score matching. Results: A total of 10,320 patients, including 2797 patients in the LMVG, 4646 patients in the HVG, and 2877 patients in the VHVG, were identified. Propensity score matching yielded 2002 patients in each hospital volume group, with an improved balance of confounding variables between the three groups. The bleeding rates in the LMVG, HVG, and VHVG were 4.3%, 3.7%, and 4.9%, respectively, and no significant difference was noted between the three groups. Conclusions: The bleeding rate after ESD for EGC did not differ between hospitals in Japan. The finding indicated that ESD for EGC is equally feasible across Japanese hospitals of different volumes regarding bleeding after ESD.
KW - Bleeding
KW - Early gastric cancer
KW - Endoscopic submucosal dissection
KW - Hospital volume
UR - http://www.scopus.com/inward/record.url?scp=85114302628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114302628&partnerID=8YFLogxK
U2 - 10.1007/s00464-021-08721-6
DO - 10.1007/s00464-021-08721-6
M3 - Article
C2 - 34494147
AN - SCOPUS:85114302628
SN - 0930-2794
VL - 36
SP - 4004
EP - 4013
JO - Surgical Endoscopy and Other Interventional Techniques
JF - Surgical Endoscopy and Other Interventional Techniques
IS - 6
ER -